Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial

DOI: 10.1111/dom.12803
Diabetes, Obesity and Metabolism, 2017, 19, 208-215.

#	Paper	IF	Citations
60	Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion. *Diabetes Technology and Therapeutics*, **2017**, 19, 25-33	8.1	49
59	Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus. *Pediatric Diabetes*, **2017**, 18, 903-910	3.6	39
58	Insulin analogues in type 1 diabetes mellitus: getting better all the time. *Nature Reviews Endocrinology*, **2017**, 13, 385-399	15.2	94
57	Faster insulin action is associated with improved glycaemic outcomes during closed-loop insulin delivery and sensor-augmented pump therapy in adults with type 1 diabetes. *Diabetes, Obesity and Metabolism*, **2017**, 19, 1485-1489	6.7	6
56	Des innovations technologiques au service de l□njection d□nsuline. *Medecine Des Maladies Metaboliques*, **2017**, 11, 416-424	0.1	2
55	Pharmacological aspects of closed loop insulin delivery for type 1 diabetes. *Current Opinion in Pharmacology*, **2017**, 36, 29-33	5.1	1
54	Insulin Management Strategies for Exercise in Diabetes. *Canadian Journal of Diabetes*, **2017**, 41, 507-516	2.1	13
53	Pharmacological Properties of Faster-Acting Insulin Aspart. *Current Diabetes Reports*, **2017**, 17, 101	5.6	17
52	Rapid-Acting and Human Insulins: Hexamer Dissociation Kinetics upon Dilution of the Pharmaceutical Formulation. *Pharmaceutical Research*, **2017**, 34, 2270-2286	4.5	19
51	Aktueller Stand der klassischen Insulinpumpentherapie. *Diabetologe*, **2017**, 13, 161-170	0.2	1
50	Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial. *Diabetes, Obesity and Metabolism*, **2017**, 19, 208-215	6.7	50
49	Insulin Pumps. *Diabetes Technology and Therapeutics*, **2018**, 20, S30-S40	8.1	3
48	Efficacy and Safety of Rapid-Acting Insulin Analogs in Special Populations with Type 1 Diabetes or Gestational Diabetes: Systematic Review and Meta-Analysis. *Diabetes Therapy*, **2018**, 9, 891-917	3.6	15
47	Blood glucose monitoring during aerobic and anaerobic physical exercise using a new artificial pancreas system. *Endocrinologia, Diabetes Y Nutrici□*, **2018**, 65, 342-347	1.3	5
46	Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects With Type 1 Diabetes. *Journal of Diabetes Science and Technology*, **2018**, 12, 145-151	4.1	29
45	Lessons for modern insulin development. *Diabetic Medicine*, **2018**, 35, 1320-1328	3.5	9
44	Emerging Technologies for Diabetes Care. *Diabetes Technology and Therapeutics*, **2018**, 20, S278-S284	8.1	21

43	Blood glucose monitoring during aerobic and anaerobic physical exercise using a new artificial pancreas system. *Endocrinología Diabetes Y Nutrición (English Ed)*, **2018**, 65, 342-347	0.1	0
42	Faster Insulin Aspart: A New Bolus Option for Diabetes Mellitus. *Clinical Pharmacokinetics*, **2019**, 58, 421-430	6.2	11
41	Glycaemic variability: The under-recognized therapeutic target in type 1 diabetes care. *Diabetes, Obesity and Metabolism*, **2019**, 21, 2599-2608	6.7	21
40	Short-term fully closed-loop insulin delivery using faster insulin aspart compared with standard insulin aspart in type 2 diabetes. *Diabetes, Obesity and Metabolism*, **2019**, 21, 2718-2722	6.7	8
39	Realizing a Closed-Loop (Artificial Pancreas) System for the Treatment of Type 1 Diabetes. *Endocrine Reviews*, **2019**, 40, 1521-1546	27.2	31
38	Use of fast-acting insulin aspart in insulin pump therapy in clinical practice. *Diabetes, Obesity and Metabolism*, **2019**, 21, 2039-2047	6.7	25
37	Fast-Acting Insulin Aspart and the Need for New Mealtime Insulin Analogues in Adults With Type 1 and Type 2 Diabetes: A Canadian Perspective. *Canadian Journal of Diabetes*, **2019**, 43, 515-523	2.1	21
36	BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study. *Diabetes, Obesity and Metabolism*, **2019**, 21, 1066-1070	6.7	22
35	A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5). *Diabetes, Obesity and Metabolism*, **2019**, 21, 961-967	6.7	34
34	Are newer insulin analogues better for people with Type 1 diabetes?. *Diabetic Medicine*, **2020**, 37, 522-531	3.5	3
33	Faster Compared With Standard Insulin Aspart During Day-and-Night Fully Closed-Loop Insulin Therapy in Type 1 Diabetes: A Double-Blind Randomized Crossover Trial. *Diabetes Care*, **2020**, 43, 29-36	14.6	39
32	Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences. *Clinical Pharmacokinetics*, **2020**, 59, 155-172	6.2	17
31	Biosimilars and Novel Insulins. *American Journal of Therapeutics*, **2020**, 27, e52-e61	1	3
30	Insulin Pump Therapy. *American Journal of Therapeutics*, **2020**, 27, e30-e41	1	11
29	Biosynthetic Human Insulin and Insulin Analogs. *American Journal of Therapeutics*, **2020**, 27, e42-e51	1	10
28	Effect of Afrezza on Glucose Dynamics During HCL Treatment. *Diabetes Care*, **2020**, 43, 2146-2152	14.6	4
27	Pharmacokinetics of Faster and Standard Insulin Aspart During Fully Closed-Loop Insulin Delivery in Type 2 Diabetes. *Diabetes Technology and Therapeutics*, **2020**, 22, 691-696	8.1	3
26	An ultrafast insulin formulation enabled by high-throughput screening of engineered polymeric excipients. *Science Translational Medicine*, **2020**, 12,	17.5	18

25	Where Do We Stand with Closed-Loop Systems and Their Challenges?. *Diabetes Technology and Therapeutics*, **2020**, 22, 485-491	8.1	3
24	The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications. *Diabetes, Obesity and Metabolism*, **2020**, 22, 743-754	6.7	28
23	Stable Monomeric Insulin Formulations Enabled by Supramolecular PEGylation of Insulin Analogues. *Advanced Therapeutics*, **2020**, 3, 1900094	4.9	14
22	The burden of type 2 diabetes in Europe: Current and future aspects of insulin treatment from patient and healthcare spending perspectives. *Diabetes Research and Clinical Practice*, **2020**, 161, 108053	7.4	16
21	Fast-Acting Insulin Aspart Use with the MiniMed 670G System. *Diabetes Technology and Therapeutics*, **2021**, 23, 1-7	8.1	19
20	Fast Acting Insulin Aspart Compared with Insulin Aspart in the Medtronic 670G Hybrid Closed Loop System in Type 1 Diabetes: An Open Label Crossover Study. *Diabetes Technology and Therapeutics*, **2021**, 23, 286-292	8.1	7
19	Improvements in Glycemic Control Achieved by Altering the t Setting in the iLet Bionic Pancreas When Using Fast-Acting Insulin Aspart: A Randomized Trial. *Diabetes Therapy*, **2021**, 12, 2019-2033	3.6	3
18	Dual-hormone artificial pancreas for management of type 1 diabetes: Recent progress and future directions. *Artificial Organs*, **2021**, 45, 968-986	2.6	6
17	Glucose control using fast-acting insulin aspart in a real-world setting: A 1-year, two-centre study in people with type 1 diabetes using continuous glucose monitoring. *Diabetes, Obesity and Metabolism* , **2021**, 23, 2716-2727	6.7	4
16	CGM sensor glucose levels and insulin pump infusion set wear-time during treatment with fast-acting insulin aspart: a post hoc analysis of onset 5. *Diabetes Technology and Therapeutics*, **2021** ,	8.1	1
15	Comparable Glucose Control with Fast-Acting Insulin Aspart Versus Insulin Aspart Using a Second-Generation Hybrid Closed-Loop System During Exercise. *Diabetes Technology and Therapeutics*, **2021**,	8.1	2
14	Time spent in hypoglycemia is comparable when the same amount of exercise is performed 5 or 2 days weekly: a randomized crossover study in people with type 1 diabetes. *BMJ Open Diabetes Research and Care*, **2021**, 9,	4.5	0
13	The impact of "faster aspart" on blood glucose control in children and adolescents with type 1 diabetes treated using a sensor-augmented insulin pump. *Anales De Pediatr□a (English Edition)*, **2021** , 95, 321-329	0.4	
12	Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences. *Diabetes Mellitus*, **2020**, 23, 140-160	1.6	
11	Contr□le de la glyc□mie post-prandiale : apport des nouvelles formulations d□insuline ultra-rapides. *Medecine Des Maladies Metaboliques*, **2020**, 14, 718-726	0.1	
10	Adjunctive therapies in type 1 diabetes mellitus. *Current Opinion in Endocrinology, Diabetes and Obesity*, **2021**, 28, 8-13	4	0
9	[The impact of «faster aspart» on blood glucose control in children and adolescents with type 1 diabetes treated using a sensor-augmented insulin pump]. *Anales De Pediatr□a*, **2020**, 95, 321-321	0.2	
8	Can Faster Aspart be Used to Optimize Glycemic Control With Insulin Pump Therapy? From Expectations to Lessons Learned After a Year of Use in the United States. *Clinical Diabetes*,	2.9	0

7	Rapid-Acting Insulin Analogues: Theory and Best Clinical Practice in Type 1 and Type 2 Diabetes.. *Diabetes, Obesity and Metabolism*, **2022**,	6.7	1
6	Formulation excipients and their role in insulin stability and association state in formulation.		
5	Faster Insulin Aspart for Continuous Subcutaneous Insulin Infusion: Is It Worth It?. **2022**,		
4	Formulation Excipients and Their Role in Insulin Stability and Association State in Formulation.		
3	Chapter 10. Invasive and Implantable Glucose Sensors: Perspective for the Artificial Pancreas. **2022**, 292-304		0
2	Comparison of faster-acting aspart with insulin aspart under conditions mimicking underestimation or missed meal boluses in type 1 diabetes using closed-loop insulin delivery.		0
1	Entwicklung der Insulintherapie in der pdiatrischen Diabetologie- Auswertung des DPV-Registers von 1995-2021.		0